Every time the U.S. tries to rein in rising drug prices, we hear the same thing from pharma: Stymie our profits, and you’ll get less innovation and fewer breakthrough treatments. Does the evidence back up this constant refrain?
Chaitan Khosla, Director of Stanford ChEM-H
Craig Garthwaite, Associate Professor of Strategy, Kellogg School of Management at Northwestern University
Stacie Dusetzina, Associate Professor of Health Policy, Vanderbilt University
Check out the research for yourself and learn more on our website: http://bit.ly/tradeoffsep8
As they say in health care, there’s no such thing as a free podcast. Support our show: https://tradeoffs.org/donate
Follow us on Twitter: https://twitter.com/tradeoffspod For information regarding your data privacy, visit acast.com/privacy